Success Metrics

Clinical Success Rate
64.0%

Based on 32 completed trials

Completion Rate
64%(32/50)
Active Trials
30(30%)
Results Posted
97%(31 trials)
Terminated
18(18%)

Phase Distribution

Ph phase_4
3
3%
Ph phase_3
8
8%
Ph phase_2
46
46%
Ph not_applicable
1
1%
Ph phase_1
33
33%

Phase Distribution

33

Early Stage

46

Mid Stage

11

Late Stage

Phase Distribution91 total trials
Phase 1Safety & dosage
33(36.3%)
Phase 2Efficacy & side effects
46(50.5%)
Phase 3Large-scale testing
8(8.8%)
Phase 4Post-market surveillance
3(3.3%)
N/ANon-phased studies
1(1.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

56.1%

32 of 57 finished

Non-Completion Rate

43.9%

25 ended early

Currently Active

30

trials recruiting

Total Trials

101

all time

Status Distribution
Active(33)
Completed(32)
Terminated(25)
Other(11)

Detailed Status

Completed32
Terminated18
Active, not recruiting15
Recruiting15
unknown10
Withdrawn7

Development Timeline

Analytics

Development Status

Total Trials
101
Active
30
Success Rate
64.0%
Most Advanced
Phase 4

Trials by Phase

Phase 133 (36.3%)
Phase 246 (50.5%)
Phase 38 (8.8%)
Phase 43 (3.3%)
N/A1 (1.1%)

Trials by Status

not_yet_recruiting33%
active_not_recruiting1515%
completed3232%
suspended11%
terminated1818%
unknown1010%
recruiting1515%
withdrawn77%

Recent Activity

30 active trials
Showing 5 of 101
recruitingphase_4

Dabrafenib and/or Trametinib Rollover Study

NCT03340506
active_not_recruitingphase_2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
recruitingphase_3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NCT06475989
active_not_recruitingphase_3

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
active_not_recruitingphase_2

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111
View all 101 trials

Clinical Trials (101)

Showing 20 of 101 trialsScroll for more
NCT03340506Phase 4

Dabrafenib and/or Trametinib Rollover Study

Recruiting
NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting
NCT06475989Phase 3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruiting
NCT04940052Phase 3

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Active Not Recruiting
NCT04544111Phase 2

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active Not Recruiting
NCT03149029Phase 2

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Active Not Recruiting
NCT04201457Phase 1

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Active Not Recruiting
NCT07110246Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Recruiting
NCT03975829Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Active Not Recruiting
NCT02858921Phase 2

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active Not Recruiting
NCT07440290Phase 2

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Recruiting
NCT01989585Phase 1

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active Not Recruiting
NCT04675710Phase 2

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Active Not Recruiting
NCT02231775Phase 2

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active Not Recruiting
NCT03091257Phase 1

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Active Not Recruiting
NCT04116541Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting
NCT04238624Phase 2

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Active Not Recruiting
NCT01972347Phase 2

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Completed
NCT02910700Phase 2

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active Not Recruiting
NCT01947023Phase 1

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
101